Do analysts prefer JBDI or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JBDI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, JBDI or BGLC?

JBDI has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JBDI $8.52M 1.38 $120K N/A N/A BioNexus Gene Lab $3.13M 1.41 -$2.98M -$1.26 N/A

Do analysts recommend BGLC or CLWT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Euro Tech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BGLC or CLWT?

Euro Tech has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNexus Gene Lab $3.13M 1.41 -$2.98M -$1.26 N/A Euro Tech $13.27M 0.89 $160K N/A N/A

Do analysts prefer BGLC or SOS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SOS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BGLC or SOS?

BioNexus Gene Lab has higher earnings, but lower revenue than SOS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNexus Gene Lab $3.13M 1.41 -$2.98M -$1.26 N/A SOS $154.29M 0.08 -$97.32M N/A N/A

Is BGLC or SOS more profitable?

SOS has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. SOS's return on equity of 0.00% beat BioNexus Gene Lab's return on equity. Company Net Margins Return on Equity Return on Assets BioNexus Gene Lab -82.38% -32.92% -29.75% SOS N/A N/A N/A

Do analysts prefer BGLC or INEO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INNEOVA 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BGLC or INEO?

INNEOVA has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNexus Gene Lab $3.13M 1.41 -$2.98M -$1.26 N/A INNEOVA $58.42M 0.11 -$400K N/A N/A

Do analysts prefer BGLC or MWG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Multi Ways 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, BGLC or MWG?

Multi Ways has higher revenue and earnings than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNexus Gene Lab $3.13M 1.41 -$2.98M -$1.26 N/A Multi Ways $44.77M 0.14 $1.79M N/A N/A

BioNexus Gene Lab (BGLC) Competitors

$1.50 -0.11 (-6.83%)

Closing price 09/14/2026 03:52 PM Eastern

Extended Trading

$1.50 0.00 (0.00%)

As of 09/14/2026 04:04 PM Eastern

Compare

BGLC vs. JBDI, CLWT, SOS, INEO, and MWG

Should you buy BioNexus Gene Lab stock or one of its competitors? BioNexus Gene Lab's main competitors and comparable companies include JBDI (JBDI), Euro Tech (CLWT), SOS (SOS), INNEOVA (INEO), and Multi Ways (MWG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does BioNexus Gene Lab compare to JBDI?

JBDI (NASDAQ:JBDI) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

JBDI has a beta of -1.11, indicating that its stock price is 211% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.19, indicating that its stock price is 319% more volatile than the broader market.

JBDI has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. JBDI's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JBDI	N/A	N/A	N/A
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

In the previous week, JBDI had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for JBDI and 1 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 1.87 beat JBDI's score of 1.11 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Overall Sentiment
JBDI	Positive
BioNexus Gene Lab	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JBDI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

JBDI has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JBDI	$8.52M	1.38	$120K	N/A	N/A
BioNexus Gene Lab	$3.13M	1.41	-$2.98M	-$1.26	N/A

Summary

JBDI beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Euro Tech?

BioNexus Gene Lab (NASDAQ:BGLC) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Euro Tech had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for Euro Tech and 1 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 1.87 beat Euro Tech's score of 1.44 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Very Positive
Euro Tech	Positive

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 2.9% of Euro Tech shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 79.0% of Euro Tech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Euro Tech has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. Euro Tech's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%
Euro Tech	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Euro Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Euro Tech has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$3.13M	1.41	-$2.98M	-$1.26	N/A
Euro Tech	$13.27M	0.89	$160K	N/A	N/A

BioNexus Gene Lab has a beta of 4.19, indicating that its stock price is 319% more volatile than the broader market. Comparatively, Euro Tech has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Euro Tech beats BioNexus Gene Lab on 7 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to SOS?

BioNexus Gene Lab (NASDAQ:BGLC) and SOS (NYSE:SOS) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

BioNexus Gene Lab has higher earnings, but lower revenue than SOS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$3.13M	1.41	-$2.98M	-$1.26	N/A
SOS	$154.29M	0.08	-$97.32M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SOS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioNexus Gene Lab had 1 more articles in the media than SOS. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for SOS. BioNexus Gene Lab's average media sentiment score of 1.87 beat SOS's score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Very Positive
SOS	Neutral

BioNexus Gene Lab has a beta of 4.19, indicating that its stock price is 319% more volatile than the broader market. Comparatively, SOS has a beta of 2.6, indicating that its stock price is 160% more volatile than the broader market.

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 1.9% of SOS shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 2.7% of SOS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SOS has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. SOS's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%
SOS	N/A	N/A	N/A

Summary

BioNexus Gene Lab beats SOS on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to INNEOVA?

BioNexus Gene Lab (NASDAQ:BGLC) and INNEOVA (NASDAQ:INEO) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, INNEOVA had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for INNEOVA and 1 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 1.87 beat INNEOVA's score of 0.43 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Very Positive
INNEOVA	Neutral

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

INNEOVA has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$3.13M	1.41	-$2.98M	-$1.26	N/A
INNEOVA	$58.42M	0.11	-$400K	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INNEOVA	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INNEOVA has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. INNEOVA's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%
INNEOVA	N/A	N/A	N/A

BioNexus Gene Lab has a beta of 4.19, suggesting that its share price is 319% more volatile than the broader market. Comparatively, INNEOVA has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Summary

INNEOVA beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Multi Ways?

BioNexus Gene Lab (NASDAQ:BGLC) and Multi Ways (NYSE:MWG) are both small-cap industrials companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Multi Ways has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. Multi Ways' return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%
Multi Ways	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Multi Ways	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Multi Ways. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Multi Ways. BioNexus Gene Lab's average media sentiment score of 1.87 beat Multi Ways' score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Very Positive
Multi Ways	Neutral

Multi Ways has higher revenue and earnings than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$3.13M	1.41	-$2.98M	-$1.26	N/A
Multi Ways	$44.77M	0.14	$1.79M	N/A	N/A

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 0.8% of Multi Ways shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioNexus Gene Lab has a beta of 4.19, indicating that its share price is 319% more volatile than the broader market. Comparatively, Multi Ways has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

BioNexus Gene Lab beats Multi Ways on 7 of the 12 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$4.72M	$9.26B	$10.31B	$13.98B
Dividend Yield	N/A	3.49%	97.17%	11.71%
P/E Ratio	-1.19	27.00	25.56	25.37
Price / Sales	1.41	22.43	327.82	75.94
Price / Cash	N/A	47.45	23.85	34.96
Price / Book	0.42	3.71	4.83	6.24
Net Income	-$2.98M	$372.29M	$612.13M	$358.08M
7 Day Performance	7.91%	-1.78%	0.38%	-0.70%
1 Month Performance	-4.46%	-5.92%	-3.59%	-2.76%
1 Year Performance	-70.12%	3.95%	6.10%	6.72%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.6113 of 5 stars	$1.50 -6.8%	N/A	-72.4%	$4.72M	$3.13M	N/A	30	Positive News Gap Down
JBDI JBDI	0.7483 of 5 stars	$1.21 -10.7%	N/A	-72.0%	$12.85M	$8.52M	N/A	121	News Coverage Positive News
CLWT Euro Tech	1.2265 of 5 stars	$1.68 -1.8%	N/A	+0.0%	$12.70M	$13.27M	N/A	40	Positive News Short Interest Decrease Gap Down
SOS SOS	0.3533 of 5 stars	$0.77 +0.1%	N/A	-58.6%	$12.41M	$154.29M	N/A	170
INEO INNEOVA	0.3453 of 5 stars	$0.54 -5.9%	N/A	-42.1%	$6.97M	$58.42M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. JBDI, CLWT, SOS, INEO, and MWG

How does BioNexus Gene Lab compare to JBDI?

Summary

How does BioNexus Gene Lab compare to Euro Tech?

Summary

How does BioNexus Gene Lab compare to SOS?

Summary

How does BioNexus Gene Lab compare to INNEOVA?

Summary

How does BioNexus Gene Lab compare to Multi Ways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. JBDI, CLWT, SOS, INEO, and MWG

How does BioNexus Gene Lab compare to JBDI?

Do institutionals and insiders believe in JBDI or BGLC?

Which has more volatility & risk, JBDI or BGLC?

Is JBDI or BGLC more profitable?

Does the media refer more to JBDI or BGLC?

Do analysts prefer JBDI or BGLC?

Which has higher earnings & valuation, JBDI or BGLC?

Summary

How does BioNexus Gene Lab compare to Euro Tech?

Does the media favor BGLC or CLWT?

Do institutionals and insiders hold more shares of BGLC or CLWT?

Is BGLC or CLWT more profitable?

Do analysts recommend BGLC or CLWT?

Which has higher valuation and earnings, BGLC or CLWT?

Which has more risk and volatility, BGLC or CLWT?

Summary

How does BioNexus Gene Lab compare to SOS?

Which has stronger earnings and valuation, BGLC or SOS?

Do analysts prefer BGLC or SOS?

Does the media prefer BGLC or SOS?

Which has more risk and volatility, BGLC or SOS?

Do insiders and institutionals hold more shares of BGLC or SOS?

Is BGLC or SOS more profitable?

Summary

How does BioNexus Gene Lab compare to INNEOVA?

Does the media favor BGLC or INEO?

Do insiders & institutionals have more ownership in BGLC or INEO?

Which has higher earnings and valuation, BGLC or INEO?

Do analysts prefer BGLC or INEO?

Is BGLC or INEO more profitable?

Which has more risk & volatility, BGLC or INEO?

Summary

How does BioNexus Gene Lab compare to Multi Ways?

Is BGLC or MWG more profitable?

Do analysts prefer BGLC or MWG?

Does the media prefer BGLC or MWG?

Which has preferable valuation & earnings, BGLC or MWG?

Do institutionals and insiders believe in BGLC or MWG?

Which has more risk & volatility, BGLC or MWG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools